drugset / Trial / NCT04282070
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
Timeline
- Start
- 2020-03-27
- Primary completion
- 2022-04-16
- Completion
- 2022-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin paclitaxel | Unknown | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | Intravenous |